why choose us

First received: January 17, 2023

Clinical Trial: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Brain Metastases

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Brief Summary: To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.

Read more